Waldenström Macroglobulinemia Excellence Forum

Leaders in the field sharing authoritative insights and institutional best practices.
Featured
An international panel of experts compare and discuss the 3 different BTK inhibitors active in the treatment of Waldenström macroglobulinemia.
View More
Steven Treon, MD, PhD, and Christian Buske, MD, discuss recent data surrounding the use of rituximab maintenance for patients with Waldenström macroglobulinemia.
View More
Stay in the know.
OncNet Newsletter